Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Xenon ( (XENE) ) has shared an update.
Xenon Pharmaceuticals Inc. announced it will report its second quarter 2025 financial results and provide a business update on August 11, 2025. This announcement is significant as it may offer insights into the company’s financial health and strategic direction, potentially impacting its market positioning and stakeholders’ interests.
The most recent analyst rating on (XENE) stock is a Buy with a $63.00 price target. To see the full list of analyst forecasts on Xenon stock, see the XENE Stock Forecast page.
Spark’s Take on XENE Stock
According to Spark, TipRanks’ AI Analyst, XENE is a Neutral.
Xenon’s primary strengths lie in its strong financial position and positive clinical development progress, as highlighted in the earnings call. However, the absence of revenue and profitability, along with technical and valuation concerns, weigh heavily on the overall stock score.
To see Spark’s full report on XENE stock, click here.
More about Xenon
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company that specializes in discovering, developing, and delivering therapeutics aimed at addressing high unmet medical needs, particularly in areas such as epilepsy and depression. The company is advancing an ion channel product portfolio, with Azetukalner, a selective Kv7 potassium channel opener, being its most advanced product in late-stage clinical development.
Average Trading Volume: 1,246,013
Technical Sentiment Signal: Sell
Current Market Cap: $2.34B
For an in-depth examination of XENE stock, go to TipRanks’ Overview page.